AU2010263056B2 - Structured viral peptide compositions and methods of use - Google Patents

Structured viral peptide compositions and methods of use Download PDF

Info

Publication number
AU2010263056B2
AU2010263056B2 AU2010263056A AU2010263056A AU2010263056B2 AU 2010263056 B2 AU2010263056 B2 AU 2010263056B2 AU 2010263056 A AU2010263056 A AU 2010263056A AU 2010263056 A AU2010263056 A AU 2010263056A AU 2010263056 B2 AU2010263056 B2 AU 2010263056B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid positions
amino acids
hydrocarbon staple
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010263056A
Other languages
English (en)
Other versions
AU2010263056A1 (en
Inventor
Gregory Bird
Loren D. Walensky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2010263056A1 publication Critical patent/AU2010263056A1/en
Application granted granted Critical
Publication of AU2010263056B2 publication Critical patent/AU2010263056B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2010263056A 2009-06-18 2010-06-18 Structured viral peptide compositions and methods of use Ceased AU2010263056B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21820909P 2009-06-18 2009-06-18
US61/218,209 2009-06-18
PCT/US2010/039223 WO2010148335A2 (en) 2009-06-18 2010-06-18 Structured viral peptide compositions and methods of use

Publications (2)

Publication Number Publication Date
AU2010263056A1 AU2010263056A1 (en) 2011-11-17
AU2010263056B2 true AU2010263056B2 (en) 2016-01-07

Family

ID=43357076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010263056A Ceased AU2010263056B2 (en) 2009-06-18 2010-06-18 Structured viral peptide compositions and methods of use

Country Status (6)

Country Link
US (2) US9822165B2 (enExample)
EP (3) EP3698811A1 (enExample)
JP (1) JP5908832B2 (enExample)
AU (1) AU2010263056B2 (enExample)
CA (2) CA3037721A1 (enExample)
WO (1) WO2010148335A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
CA2833171C (en) 2011-04-15 2021-08-31 Loren D. Walensky Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
CN104254563B (zh) * 2012-02-24 2017-09-12 大金工业株式会社 氟橡胶组合物
WO2014144148A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
US9644002B2 (en) 2013-07-25 2017-05-09 Yale University Allosteric modulators of EGFR and constitutively active mutants
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
US10464975B2 (en) 2015-07-02 2019-11-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｆｌ－１と結合するペプチド
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
CN109069578A (zh) 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 用于治疗感染的钉合的细胞内靶向抗微生物肽
EP3214093A1 (en) * 2016-03-03 2017-09-06 Fondation The Ark Fusion respiratory syncytial virus inhibitors and use thereof
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
ES2935622T3 (es) 2016-08-26 2023-03-08 Dana Farber Cancer Inst Inc Polipéptidos y miméticos de bcl-w para el tratamiento o la prevención de la neuropatía periférica y la pérdida auditiva inducidas por la quimioterapia
US12344643B2 (en) 2016-12-07 2025-07-01 The University Of Chicago Compositions and methods for inhibition of FOXP3
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
WO2018200323A1 (en) 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
AU2018304230A1 (en) 2017-07-19 2020-02-06 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
WO2019090015A1 (en) 2017-11-03 2019-05-09 Yale University Peptidic materials that traffic efficiently to the cell cytosol and nucleus
WO2019094830A1 (en) * 2017-11-10 2019-05-16 Washington University Mitofusin modulation agents and methods of use thereof
CN120118207A (zh) 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
WO2019118719A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
EP3765852A1 (en) 2018-03-14 2021-01-20 Dana Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
WO2020060975A1 (en) 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
JP7727551B2 (ja) 2019-04-18 2025-08-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 構造的に安定化されたペプチドによるユビキチンおよびユビキチン様ｅ１活性化酵素の選択的標的化
WO2021126827A1 (en) 2019-12-16 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
WO2021127493A1 (en) 2019-12-20 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
JP7894318B2 (ja) * 2020-03-04 2026-07-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用
WO2021216845A1 (en) 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
US10975126B1 (en) * 2020-04-23 2021-04-13 King Faisal University MERS-CoV inhibitor peptides
AU2021262752A1 (en) 2020-04-27 2022-10-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and HDMX-selective p53 peptides and uses thereof
WO2022081827A1 (en) 2020-10-14 2022-04-21 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2022098848A1 (en) 2020-11-05 2022-05-12 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
US20240317826A1 (en) * 2021-05-11 2024-09-26 Albert Einstein College Of Medicine Compositions and methods for treating and/or identifying an agent for treating hiv-1 infections
MX2024002824A (es) 2021-09-08 2024-06-28 Dana Farber Cancer Inst Inc Conjugados antivirales de peptido de coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2)-colesterol estructuralmente engrapados y usos de los mismos.
EP4518900A1 (en) 2022-05-04 2025-03-12 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2025090958A1 (en) * 2023-10-27 2025-05-01 Red Queen Therapeutics, Inc. Antiviral structurally-stapled paramyxoviridae peptide-cholesterol conjugates and uses thereof
WO2026024936A2 (en) 2024-07-25 2026-01-29 Dana-Farber Cancer Institute, Inc. Bh4 domain peptides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CA2270869A1 (en) 1996-11-06 1998-05-14 Genentech, Inc. Constrained helical peptides and methods of making same
JP2003529319A (ja) 1999-01-08 2003-10-07 キャロル ディ． ウエイス， ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
US20060241027A1 (en) 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
WO2005034842A2 (en) 2003-05-19 2005-04-21 Progenics Pharmaceuticals, Inc. Peptides useful as hiv fusion inhibitors
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
US8003332B2 (en) 2005-05-06 2011-08-23 Albert Einstein College Of Medicine Of Yeshiva University Inhibition of membrane fusion proteins
US20090035707A1 (en) * 2007-08-01 2009-02-05 Yubing Wang Rheology-controlled conductive materials, methods of production and uses thereof
US20110033522A1 (en) * 2007-09-26 2011-02-10 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) * 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same

Also Published As

Publication number Publication date
US10273290B2 (en) 2019-04-30
WO2010148335A2 (en) 2010-12-23
CA3037721A1 (en) 2010-12-23
JP5908832B2 (ja) 2016-04-26
EP2442829A4 (en) 2017-02-15
US20180037636A1 (en) 2018-02-08
EP2442829B1 (en) 2021-02-24
CA2761568A1 (en) 2010-12-23
EP3698810A1 (en) 2020-08-26
WO2010148335A3 (en) 2011-02-10
US9822165B2 (en) 2017-11-21
US20120141527A1 (en) 2012-06-07
JP2012530720A (ja) 2012-12-06
AU2010263056A1 (en) 2011-11-17
EP2442829A2 (en) 2012-04-25
CA2761568C (en) 2020-10-13
EP3698811A1 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
US10273290B2 (en) Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides
CA2713089C (en) Compositions and methods for the treatment of viral infections
Guo et al. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
AU2021221582B2 (en) Compositions and methods related to HIV-1 immunogens
US6271198B1 (en) Constrained helical peptides and methods of making same
JP5069558B2 (ja) ＨＩＶｇｐ４１融合中間物質の安定したペプチド模倣薬
Qi et al. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice
US20150071954A1 (en) Stable peptide mimetics of the hiv-1 gp41 pre-hairpin intermediate
WO2010041237A2 (en) Cyclic v3 peptides for anti hiv-1 vaccine
EP2451826A1 (en) Alphabodies for hiv entry inhibition
Woof et al. Antonis Mirsaliotis, Kulpash Nurkiyanova, Daniel Lamb

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired